Farther Finance Advisors LLC Has $44,000 Stock Holdings in Enanta Pharmaceuticals, Inc. $ENTA

Farther Finance Advisors LLC increased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 11,558.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,829 shares of the biotechnology company’s stock after purchasing an additional 5,779 shares during the quarter. Farther Finance Advisors LLC’s holdings in Enanta Pharmaceuticals were worth $44,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after buying an additional 449,945 shares during the period. Acadian Asset Management LLC lifted its position in Enanta Pharmaceuticals by 2.1% in the 1st quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock valued at $4,782,000 after acquiring an additional 17,613 shares in the last quarter. Stonepine Capital Management LLC lifted its position in Enanta Pharmaceuticals by 78.0% in the 1st quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company’s stock valued at $3,261,000 after acquiring an additional 258,842 shares in the last quarter. AQR Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock worth $1,971,000 after purchasing an additional 311,010 shares during the period. Finally, Trexquant Investment LP increased its holdings in Enanta Pharmaceuticals by 113.4% during the 1st quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company’s stock worth $1,601,000 after purchasing an additional 154,105 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Up 9.9%

Shares of NASDAQ ENTA opened at $11.35 on Tuesday. The firm has a market cap of $242.66 million, a P/E ratio of -2.63 and a beta of 0.89. The business’s 50 day moving average is $8.43 and its 200-day moving average is $7.03. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.09 and a 1-year high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%. Analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $14.00 to $20.00 in a research note on Wednesday, October 1st. Westpark Capital lifted their target price on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Saturday, September 27th. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 22nd. Finally, JMP Securities increased their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.